Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins
- 1 September 2005
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 6 (5), 326-333
- https://doi.org/10.1111/j.1468-1293.2005.00316.x
Abstract
Dyslipidaemia has become a common problem in HIV disease, especially in patients on current antiretroviral therapy. However, the pathogenic mechanisms involved are not well understood or documented using conventional lipid measurements. Using a cross-sectional design, the prevalence of abnormal standard lipid measurements and novel biomarkers for abnormal lipid metabolism was determined in 271 HIV-positive men from two HIV clinics in Atlanta, GA, USA. A total of 147 men were treated with protease inhibitors (PIs) for >3 months (54%), 84 were treated with nonnucleoside reverse transcriptase inhibitors (NNRTIs) for >3 months (31%) and 40 had not received antiretroviral therapy in the past 3 months (15%). Patients being treated with a PI had higher total cholesterol and triglyceride (TG) levels than patients on no therapy (P<0.05 for each). Patients in the NNRTI group had higher TG, lower high-density lipoprotein (HDL) levels, and higher low-density lipoprotein (LDL) levels than patients on no therapy (P<0.05 for each). Patients treated with either PIs or NNRTIs were more likely to have higher apolipoprotein CIII (apoCIII) levels (P<0.05 for each) than patients on no therapy. Elevated TG was associated with disproportionably elevated apoCIII levels in both treatment groups. In this cross-sectional study of HIV-infected men, either PI or NNRTI therapy elevated levels of TG and apoCIII. Higher concentrations of apoCIII in apoB-containing lipoproteins [very low-density lipoproteins (VLDLs), intermediate density lipoprotein (IDL) and LDLs] have been predictive of an increased incidence of coronary events in clinical trials and more rapid progression of coronary lesions measured by angiography. These findings, on a background of an older population with additional risk factors of smoking and diabetes, portend future atherosclerotic events in these patients.Keywords
This publication has 45 references indexed in Scilit:
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004
- Association between Protease Inhibitor Use and Increased Cardiovascular Risk in Patients Infected with Human Immunodeficiency Virus: A Systematic ReviewClinical Infectious Diseases, 2003
- Differentiating hyperlipidaemia associated with antiretroviral therapyAIDS, 2003
- Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitorsAmerican Heart Journal, 2002
- Alterations of Apolipoprotein B Metabolism in HIV-Infected Patients With Antiretroviral Combination TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Apoprotein C-III and E-Containing Lipoparticles Are Markedly Increased in HIV-Infected Patients Treated with Protease Inhibitors: Association with the Development of LipodystrophyJournal of Clinical Endocrinology & Metabolism, 2001
- Increase of Atherogenic Plasma Profile in HIV-Infected Patients Treated With Protease Inhibitor???Containing RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Absence of Association Between Individual Thymidine Analogues or Nonnucleoside Analogues and Lipid Abnormalities in HIV-1–Infected Persons on Initial TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.JCI Insight, 1986
- Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoproteinBiochemical and Biophysical Research Communications, 1972